Report cover image

Global Remicade Biosimilar Market Outlook and Growth Opportunities 2025

Publisher APO Research, Inc.
Published Oct 20, 2025
Length 197 Pages
SKU # APRC20556120

Description

Summary

According to APO Research, the global Remicade Biosimilar market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.

The North American market for Remicade Biosimilar is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The Asia-Pacific market for Remicade Biosimilar is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

In China, the Remicade Biosimilar market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The Europe market for Remicade Biosimilar is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Major global companies in the Remicade Biosimilar market include Walvax Biotechnology, Livzon Pharmaceutical, Hualan Biological Engineering, Hisun Pharmaceutical, Fosun Pharmaceutical, Anke Biotechnology, Synthon Pharmaceuticals, Novartis (Sandoz) and Merck Serono (Merck Group), etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Remicade Biosimilar, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Remicade Biosimilar, also provides the sales of main regions and countries. Of the upcoming market potential for Remicade Biosimilar, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Remicade Biosimilar sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Remicade Biosimilar market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Remicade Biosimilar sales, projected growth trends, production technology, application and end-user industry.


Remicade Biosimilar Segment by Company


Walvax Biotechnology
Livzon Pharmaceutical
Hualan Biological Engineering
Hisun Pharmaceutical
Fosun Pharmaceutical
Anke Biotechnology
Synthon Pharmaceuticals
Novartis (Sandoz)
Merck Serono (Merck Group)
LG Life Sciences
Hospira
Genentech (Roche Group)
Celltrion
Biogen idec Inc.
Biocon

Remicade Biosimilar Segment by Type


100mg/10ml
500mg/50ml

Remicade Biosimilar Segment by Application


Blood Disorders
Oncology Diseases

Remicade Biosimilar Segment by Region


North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Study Objectives

1. To analyze and research the global Remicade Biosimilar status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Remicade Biosimilar market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Remicade Biosimilar significant trends, drivers, influence factors in global and regions.
6. To analyze Remicade Biosimilar competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Remicade Biosimilar market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Remicade Biosimilar and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Remicade Biosimilar.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Remicade Biosimilar market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Remicade Biosimilar industry.
Chapter 3: Detailed analysis of Remicade Biosimilar manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Remicade Biosimilar in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Remicade Biosimilar in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

197 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Market Growth Prospects
1.2.1 Global Remicade Biosimilar Sales Value (2020-2031)
1.2.2 Global Remicade Biosimilar Sales Volume (2020-2031)
1.2.3 Global Remicade Biosimilar Sales Average Price (2020-2031)
1.3 Assumptions and Limitations
1.4 Study Goals and Objectives
2 Remicade Biosimilar Market Dynamics
2.1 Remicade Biosimilar Industry Trends
2.2 Remicade Biosimilar Industry Drivers
2.3 Remicade Biosimilar Industry Opportunities and Challenges
2.4 Remicade Biosimilar Industry Restraints
3 Remicade Biosimilar Market by Company
3.1 Global Remicade Biosimilar Company Revenue Ranking in 2024
3.2 Global Remicade Biosimilar Revenue by Company (2020-2025)
3.3 Global Remicade Biosimilar Sales Volume by Company (2020-2025)
3.4 Global Remicade Biosimilar Average Price by Company (2020-2025)
3.5 Global Remicade Biosimilar Company Ranking (2023-2025)
3.6 Global Remicade Biosimilar Company Manufacturing Base and Headquarters
3.7 Global Remicade Biosimilar Company Product Type and Application
3.8 Global Remicade Biosimilar Company Establishment Date
3.9 Market Competitive Analysis
3.9.1 Global Remicade Biosimilar Market Concentration Ratio (CR5 and HHI)
3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
3.9.3 2024 Remicade Biosimilar Tier 1, Tier 2, and Tier 3 Companies
3.10 Mergers and Acquisitions Expansion
4 Remicade Biosimilar Market by Type
4.1 Remicade Biosimilar Type Introduction
4.1.1 100mg/10ml
4.1.2 500mg/50ml
4.2 Global Remicade Biosimilar Sales Volume by Type
4.2.1 Global Remicade Biosimilar Sales Volume by Type (2020 VS 2024 VS 2031)
4.2.2 Global Remicade Biosimilar Sales Volume by Type (2020-2031)
4.2.3 Global Remicade Biosimilar Sales Volume Share by Type (2020-2031)
4.3 Global Remicade Biosimilar Sales Value by Type
4.3.1 Global Remicade Biosimilar Sales Value by Type (2020 VS 2024 VS 2031)
4.3.2 Global Remicade Biosimilar Sales Value by Type (2020-2031)
4.3.3 Global Remicade Biosimilar Sales Value Share by Type (2020-2031)
5 Remicade Biosimilar Market by Application
5.1 Remicade Biosimilar Application Introduction
5.1.1 Blood Disorders
5.1.2 Oncology Diseases
5.2 Global Remicade Biosimilar Sales Volume by Application
5.2.1 Global Remicade Biosimilar Sales Volume by Application (2020 VS 2024 VS 2031)
5.2.2 Global Remicade Biosimilar Sales Volume by Application (2020-2031)
5.2.3 Global Remicade Biosimilar Sales Volume Share by Application (2020-2031)
5.3 Global Remicade Biosimilar Sales Value by Application
5.3.1 Global Remicade Biosimilar Sales Value by Application (2020 VS 2024 VS 2031)
5.3.2 Global Remicade Biosimilar Sales Value by Application (2020-2031)
5.3.3 Global Remicade Biosimilar Sales Value Share by Application (2020-2031)
6 Remicade Biosimilar Regional Sales and Value Analysis
6.1 Global Remicade Biosimilar Sales by Region: 2020 VS 2024 VS 2031
6.2 Global Remicade Biosimilar Sales by Region (2020-2031)
6.2.1 Global Remicade Biosimilar Sales by Region: 2020-2025
6.2.2 Global Remicade Biosimilar Sales by Region (2026-2031)
6.3 Global Remicade Biosimilar Sales Value by Region: 2020 VS 2024 VS 2031
6.4 Global Remicade Biosimilar Sales Value by Region (2020-2031)
6.4.1 Global Remicade Biosimilar Sales Value by Region: 2020-2025
6.4.2 Global Remicade Biosimilar Sales Value by Region (2026-2031)
6.5 Global Remicade Biosimilar Market Price Analysis by Region (2020-2025)
6.6 North America
6.6.1 North America Remicade Biosimilar Sales Value (2020-2031)
6.6.2 North America Remicade Biosimilar Sales Value Share by Country, 2024 VS 2031
6.7 Europe
6.7.1 Europe Remicade Biosimilar Sales Value (2020-2031)
6.7.2 Europe Remicade Biosimilar Sales Value Share by Country, 2024 VS 2031
6.8 Asia-Pacific
6.8.1 Asia-Pacific Remicade Biosimilar Sales Value (2020-2031)
6.8.2 Asia-Pacific Remicade Biosimilar Sales Value Share by Country, 2024 VS 2031
6.9 South America
6.9.1 South America Remicade Biosimilar Sales Value (2020-2031)
6.9.2 South America Remicade Biosimilar Sales Value Share by Country, 2024 VS 2031
6.10 Middle East & Africa
6.10.1 Middle East & Africa Remicade Biosimilar Sales Value (2020-2031)
6.10.2 Middle East & Africa Remicade Biosimilar Sales Value Share by Country, 2024 VS 2031
7 Remicade Biosimilar Country-level Sales and Value Analysis
7.1 Global Remicade Biosimilar Sales by Country: 2020 VS 2024 VS 2031
7.2 Global Remicade Biosimilar Sales Value by Country: 2020 VS 2024 VS 2031
7.3 Global Remicade Biosimilar Sales by Country (2020-2031)
7.3.1 Global Remicade Biosimilar Sales by Country (2020-2025)
7.3.2 Global Remicade Biosimilar Sales by Country (2026-2031)
7.4 Global Remicade Biosimilar Sales Value by Country (2020-2031)
7.4.1 Global Remicade Biosimilar Sales Value by Country (2020-2025)
7.4.2 Global Remicade Biosimilar Sales Value by Country (2026-2031)
7.5 USA
7.5.1 USA Remicade Biosimilar Sales Value Growth Rate (2020-2031)
7.5.2 USA Remicade Biosimilar Sales Value Share by Type, 2024 VS 2031
7.5.3 USA Remicade Biosimilar Sales Value Share by Application, 2024 VS 2031
7.6 Canada
7.6.1 Canada Remicade Biosimilar Sales Value Growth Rate (2020-2031)
7.6.2 Canada Remicade Biosimilar Sales Value Share by Type, 2024 VS 2031
7.6.3 Canada Remicade Biosimilar Sales Value Share by Application, 2024 VS 2031
7.7 Mexico
7.6.1 Mexico Remicade Biosimilar Sales Value Growth Rate (2020-2031)
7.6.2 Mexico Remicade Biosimilar Sales Value Share by Type, 2024 VS 2031
7.6.3 Mexico Remicade Biosimilar Sales Value Share by Application, 2024 VS 2031
7.8 Germany
7.8.1 Germany Remicade Biosimilar Sales Value Growth Rate (2020-2031)
7.8.2 Germany Remicade Biosimilar Sales Value Share by Type, 2024 VS 2031
7.8.3 Germany Remicade Biosimilar Sales Value Share by Application, 2024 VS 2031
7.9 France
7.9.1 France Remicade Biosimilar Sales Value Growth Rate (2020-2031)
7.9.2 France Remicade Biosimilar Sales Value Share by Type, 2024 VS 2031
7.9.3 France Remicade Biosimilar Sales Value Share by Application, 2024 VS 2031
7.10 U.K.
7.10.1 U.K. Remicade Biosimilar Sales Value Growth Rate (2020-2031)
7.10.2 U.K. Remicade Biosimilar Sales Value Share by Type, 2024 VS 2031
7.10.3 U.K. Remicade Biosimilar Sales Value Share by Application, 2024 VS 2031
7.11 Italy
7.11.1 Italy Remicade Biosimilar Sales Value Growth Rate (2020-2031)
7.11.2 Italy Remicade Biosimilar Sales Value Share by Type, 2024 VS 2031
7.11.3 Italy Remicade Biosimilar Sales Value Share by Application, 2024 VS 2031
7.12 Spain
7.12.1 Spain Remicade Biosimilar Sales Value Growth Rate (2020-2031)
7.12.2 Spain Remicade Biosimilar Sales Value Share by Type, 2024 VS 2031
7.12.3 Spain Remicade Biosimilar Sales Value Share by Application, 2024 VS 2031
7.13 Russia
7.13.1 Russia Remicade Biosimilar Sales Value Growth Rate (2020-2031)
7.13.2 Russia Remicade Biosimilar Sales Value Share by Type, 2024 VS 2031
7.13.3 Russia Remicade Biosimilar Sales Value Share by Application, 2024 VS 2031
7.14 Netherlands
7.14.1 Netherlands Remicade Biosimilar Sales Value Growth Rate (2020-2031)
7.14.2 Netherlands Remicade Biosimilar Sales Value Share by Type, 2024 VS 2031
7.14.3 Netherlands Remicade Biosimilar Sales Value Share by Application, 2024 VS 2031
7.15 Nordic Countries
7.15.1 Nordic Countries Remicade Biosimilar Sales Value Growth Rate (2020-2031)
7.15.2 Nordic Countries Remicade Biosimilar Sales Value Share by Type, 2024 VS 2031
7.15.3 Nordic Countries Remicade Biosimilar Sales Value Share by Application, 2024 VS 2031
7.16 China
7.16.1 China Remicade Biosimilar Sales Value Growth Rate (2020-2031)
7.16.2 China Remicade Biosimilar Sales Value Share by Type, 2024 VS 2031
7.16.3 China Remicade Biosimilar Sales Value Share by Application, 2024 VS 2031
7.17 Japan
7.17.1 Japan Remicade Biosimilar Sales Value Growth Rate (2020-2031)
7.17.2 Japan Remicade Biosimilar Sales Value Share by Type, 2024 VS 2031
7.17.3 Japan Remicade Biosimilar Sales Value Share by Application, 2024 VS 2031
7.18 South Korea
7.18.1 South Korea Remicade Biosimilar Sales Value Growth Rate (2020-2031)
7.18.2 South Korea Remicade Biosimilar Sales Value Share by Type, 2024 VS 2031
7.18.3 South Korea Remicade Biosimilar Sales Value Share by Application, 2024 VS 2031
7.19 India
7.19.1 India Remicade Biosimilar Sales Value Growth Rate (2020-2031)
7.19.2 India Remicade Biosimilar Sales Value Share by Type, 2024 VS 2031
7.19.3 India Remicade Biosimilar Sales Value Share by Application, 2024 VS 2031
7.20 Australia
7.20.1 Australia Remicade Biosimilar Sales Value Growth Rate (2020-2031)
7.20.2 Australia Remicade Biosimilar Sales Value Share by Type, 2024 VS 2031
7.20.3 Australia Remicade Biosimilar Sales Value Share by Application, 2024 VS 2031
7.21 Southeast Asia
7.21.1 Southeast Asia Remicade Biosimilar Sales Value Growth Rate (2020-2031)
7.21.2 Southeast Asia Remicade Biosimilar Sales Value Share by Type, 2024 VS 2031
7.21.3 Southeast Asia Remicade Biosimilar Sales Value Share by Application, 2024 VS 2031
7.22 Brazil
7.22.1 Brazil Remicade Biosimilar Sales Value Growth Rate (2020-2031)
7.22.2 Brazil Remicade Biosimilar Sales Value Share by Type, 2024 VS 2031
7.22.3 Brazil Remicade Biosimilar Sales Value Share by Application, 2024 VS 2031
7.23 Argentina
7.23.1 Argentina Remicade Biosimilar Sales Value Growth Rate (2020-2031)
7.23.2 Argentina Remicade Biosimilar Sales Value Share by Type, 2024 VS 2031
7.23.3 Argentina Remicade Biosimilar Sales Value Share by Application, 2024 VS 2031
7.24 Chile
7.24.1 Chile Remicade Biosimilar Sales Value Growth Rate (2020-2031)
7.24.2 Chile Remicade Biosimilar Sales Value Share by Type, 2024 VS 2031
7.24.3 Chile Remicade Biosimilar Sales Value Share by Application, 2024 VS 2031
7.25 Colombia
7.25.1 Colombia Remicade Biosimilar Sales Value Growth Rate (2020-2031)
7.25.2 Colombia Remicade Biosimilar Sales Value Share by Type, 2024 VS 2031
7.25.3 Colombia Remicade Biosimilar Sales Value Share by Application, 2024 VS 2031
7.26 Peru
7.26.1 Peru Remicade Biosimilar Sales Value Growth Rate (2020-2031)
7.26.2 Peru Remicade Biosimilar Sales Value Share by Type, 2024 VS 2031
7.26.3 Peru Remicade Biosimilar Sales Value Share by Application, 2024 VS 2031
7.27 Saudi Arabia
7.27.1 Saudi Arabia Remicade Biosimilar Sales Value Growth Rate (2020-2031)
7.27.2 Saudi Arabia Remicade Biosimilar Sales Value Share by Type, 2024 VS 2031
7.27.3 Saudi Arabia Remicade Biosimilar Sales Value Share by Application, 2024 VS 2031
7.28 Israel
7.28.1 Israel Remicade Biosimilar Sales Value Growth Rate (2020-2031)
7.28.2 Israel Remicade Biosimilar Sales Value Share by Type, 2024 VS 2031
7.28.3 Israel Remicade Biosimilar Sales Value Share by Application, 2024 VS 2031
7.29 UAE
7.29.1 UAE Remicade Biosimilar Sales Value Growth Rate (2020-2031)
7.29.2 UAE Remicade Biosimilar Sales Value Share by Type, 2024 VS 2031
7.29.3 UAE Remicade Biosimilar Sales Value Share by Application, 2024 VS 2031
7.30 Turkey
7.30.1 Turkey Remicade Biosimilar Sales Value Growth Rate (2020-2031)
7.30.2 Turkey Remicade Biosimilar Sales Value Share by Type, 2024 VS 2031
7.30.3 Turkey Remicade Biosimilar Sales Value Share by Application, 2024 VS 2031
7.31 Iran
7.31.1 Iran Remicade Biosimilar Sales Value Growth Rate (2020-2031)
7.31.2 Iran Remicade Biosimilar Sales Value Share by Type, 2024 VS 2031
7.31.3 Iran Remicade Biosimilar Sales Value Share by Application, 2024 VS 2031
7.32 Egypt
7.32.1 Egypt Remicade Biosimilar Sales Value Growth Rate (2020-2031)
7.32.2 Egypt Remicade Biosimilar Sales Value Share by Type, 2024 VS 2031
7.32.3 Egypt Remicade Biosimilar Sales Value Share by Application, 2024 VS 2031
8 Company Profiles
8.1 Walvax Biotechnology
8.1.1 Walvax Biotechnology Comapny Information
8.1.2 Walvax Biotechnology Business Overview
8.1.3 Walvax Biotechnology Remicade Biosimilar Sales, Value and Gross Margin (2020-2025)
8.1.4 Walvax Biotechnology Remicade Biosimilar Product Portfolio
8.1.5 Walvax Biotechnology Recent Developments
8.2 Livzon Pharmaceutical
8.2.1 Livzon Pharmaceutical Comapny Information
8.2.2 Livzon Pharmaceutical Business Overview
8.2.3 Livzon Pharmaceutical Remicade Biosimilar Sales, Value and Gross Margin (2020-2025)
8.2.4 Livzon Pharmaceutical Remicade Biosimilar Product Portfolio
8.2.5 Livzon Pharmaceutical Recent Developments
8.3 Hualan Biological Engineering
8.3.1 Hualan Biological Engineering Comapny Information
8.3.2 Hualan Biological Engineering Business Overview
8.3.3 Hualan Biological Engineering Remicade Biosimilar Sales, Value and Gross Margin (2020-2025)
8.3.4 Hualan Biological Engineering Remicade Biosimilar Product Portfolio
8.3.5 Hualan Biological Engineering Recent Developments
8.4 Hisun Pharmaceutical
8.4.1 Hisun Pharmaceutical Comapny Information
8.4.2 Hisun Pharmaceutical Business Overview
8.4.3 Hisun Pharmaceutical Remicade Biosimilar Sales, Value and Gross Margin (2020-2025)
8.4.4 Hisun Pharmaceutical Remicade Biosimilar Product Portfolio
8.4.5 Hisun Pharmaceutical Recent Developments
8.5 Fosun Pharmaceutical
8.5.1 Fosun Pharmaceutical Comapny Information
8.5.2 Fosun Pharmaceutical Business Overview
8.5.3 Fosun Pharmaceutical Remicade Biosimilar Sales, Value and Gross Margin (2020-2025)
8.5.4 Fosun Pharmaceutical Remicade Biosimilar Product Portfolio
8.5.5 Fosun Pharmaceutical Recent Developments
8.6 Anke Biotechnology
8.6.1 Anke Biotechnology Comapny Information
8.6.2 Anke Biotechnology Business Overview
8.6.3 Anke Biotechnology Remicade Biosimilar Sales, Value and Gross Margin (2020-2025)
8.6.4 Anke Biotechnology Remicade Biosimilar Product Portfolio
8.6.5 Anke Biotechnology Recent Developments
8.7 Synthon Pharmaceuticals
8.7.1 Synthon Pharmaceuticals Comapny Information
8.7.2 Synthon Pharmaceuticals Business Overview
8.7.3 Synthon Pharmaceuticals Remicade Biosimilar Sales, Value and Gross Margin (2020-2025)
8.7.4 Synthon Pharmaceuticals Remicade Biosimilar Product Portfolio
8.7.5 Synthon Pharmaceuticals Recent Developments
8.8 Novartis (Sandoz)
8.8.1 Novartis (Sandoz) Comapny Information
8.8.2 Novartis (Sandoz) Business Overview
8.8.3 Novartis (Sandoz) Remicade Biosimilar Sales, Value and Gross Margin (2020-2025)
8.8.4 Novartis (Sandoz) Remicade Biosimilar Product Portfolio
8.8.5 Novartis (Sandoz) Recent Developments
8.9 Merck Serono (Merck Group)
8.9.1 Merck Serono (Merck Group) Comapny Information
8.9.2 Merck Serono (Merck Group) Business Overview
8.9.3 Merck Serono (Merck Group) Remicade Biosimilar Sales, Value and Gross Margin (2020-2025)
8.9.4 Merck Serono (Merck Group) Remicade Biosimilar Product Portfolio
8.9.5 Merck Serono (Merck Group) Recent Developments
8.10 LG Life Sciences
8.10.1 LG Life Sciences Comapny Information
8.10.2 LG Life Sciences Business Overview
8.10.3 LG Life Sciences Remicade Biosimilar Sales, Value and Gross Margin (2020-2025)
8.10.4 LG Life Sciences Remicade Biosimilar Product Portfolio
8.10.5 LG Life Sciences Recent Developments
8.11 Hospira
8.11.1 Hospira Comapny Information
8.11.2 Hospira Business Overview
8.11.3 Hospira Remicade Biosimilar Sales, Value and Gross Margin (2020-2025)
8.11.4 Hospira Remicade Biosimilar Product Portfolio
8.11.5 Hospira Recent Developments
8.12 Genentech (Roche Group)
8.12.1 Genentech (Roche Group) Comapny Information
8.12.2 Genentech (Roche Group) Business Overview
8.12.3 Genentech (Roche Group) Remicade Biosimilar Sales, Value and Gross Margin (2020-2025)
8.12.4 Genentech (Roche Group) Remicade Biosimilar Product Portfolio
8.12.5 Genentech (Roche Group) Recent Developments
8.13 Celltrion
8.13.1 Celltrion Comapny Information
8.13.2 Celltrion Business Overview
8.13.3 Celltrion Remicade Biosimilar Sales, Value and Gross Margin (2020-2025)
8.13.4 Celltrion Remicade Biosimilar Product Portfolio
8.13.5 Celltrion Recent Developments
8.14 Biogen idec Inc.
8.14.1 Biogen idec Inc. Comapny Information
8.14.2 Biogen idec Inc. Business Overview
8.14.3 Biogen idec Inc. Remicade Biosimilar Sales, Value and Gross Margin (2020-2025)
8.14.4 Biogen idec Inc. Remicade Biosimilar Product Portfolio
8.14.5 Biogen idec Inc. Recent Developments
8.15 Biocon
8.15.1 Biocon Comapny Information
8.15.2 Biocon Business Overview
8.15.3 Biocon Remicade Biosimilar Sales, Value and Gross Margin (2020-2025)
8.15.4 Biocon Remicade Biosimilar Product Portfolio
8.15.5 Biocon Recent Developments
9 Value Chain and Sales Channels Analysis
9.1 Remicade Biosimilar Value Chain Analysis
9.1.1 Remicade Biosimilar Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 Remicade Biosimilar Sales Mode & Process
9.2 Remicade Biosimilar Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 Remicade Biosimilar Distributors
9.2.3 Remicade Biosimilar Customers
10 Concluding Insights
11 Appendix
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources
How Do Licenses Work?
Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.